Resolute Announces Share Repurchase Program

Resolute Forest Products Inc. (NYSE: RFP) (TSX: RFP) today announced that its board of directors authorized the repurchase of up to $100 million or 10 million of the company’s common shares, whichever occurs first. Repurchase transactions will be funded using the company’s sources of liquidity.

“Today’s announcement follows recent completion of the share repurchase program announced in March 2020, under which we repurchased 11.5 million shares for $78.3 million, representing 15% of the outstanding shares,” said Remi G. Lalonde, president and chief executive officer. “This new program will allow us to continue to act opportunistically to return capital to shareholders when conditions are right. We remain committed to a balanced approach to capital allocation, using our free cash flow to generate value for shareholders, build a stronger company and drive sustainable economic activity in the communities where we operate.”

Under the new share repurchase program, the company is authorized to repurchase from time to time shares of its outstanding common stock on the open market or in privately negotiated transactions in the United States. The timing and amount of stock repurchases will depend on a variety of factors, including market conditions as well as corporate and regulatory considerations. The share repurchase program may be suspended, modified or discontinued at any time and the company has no obligation to repurchase any amount of its common stock under the program. The repurchase program has no set expiration date. The company intends to make all repurchases in compliance with applicable regulatory guidelines and to administer the plan in accordance with applicable laws, including Rule 10b-8 of the Securities Exchange Act of 1934, as amended.
https://resolutefp.mediaroom.com/2021-12-07-Resolute-Announces-Share-Repurchase-Program

Related Posts

Canfor Subsidiary to Acquire Strategic Assets

Canfor Corporation announced that its 70%-owned subsidiary, Vida Group, has entered into an agreement to purchase three sawmills located in Sweden from Bergs Timber for a purchase price of CAD$43 million plus working capital. The three mills, which are located in Vimmerby, Mörlunda and Orrefors, Sweden, will add approximately 215 million board feet to Vida’s annual capacity. With additional investment, Vida anticipates the production capacity of the mills can be increased to 300 million board feet. After taking into account this additional production capacity, Sweden represents 22% of Canfor’s globally diversified operating platforms, plus 43% in British Columbia, 31% in the Southern United States and 4% in Alberta.

Lecta Commits to Solar Energy at Its Condat Le Lardin-Saint-Lazare mill

In keeping with its commitment to the environment and increased energy efficiency, Lecta has announced an innovative renewable energy project to harness solar radiation for thermal power to be used in manufacturing processes at its Condat Le Lardin-Saint-Lazare mill. With the help of an expert specialized in the installation of thermal power plants for the paper industry, starting this fall Lecta will have a thermal solar power plant at the mill with a capacity of 3.4 MWth. Its total surface area will be 1.4 hectares, with 45,434 square feet of solar panels deployed on the surrounding land and an ability to provide around 3,900 MW/year of energy. Panels with solar trackers, mechanical devices that orient the collectors, will follow the position of the sun during the day and convert the sun's rays into thermal energy that will be sent to the mill as hot water. Click Read More below for additional information.

UPM brings its first clinical product to market – FibDex® wound dressing

FibDex® wound dressing – made from nanofibrillar cellulose by UPM Biomedicals – has taken a significant step in its path to market, as leading medical device distributor Steripolar Oy now sells the product in Finland. FibDex is the first clinical product of renowned forest-based bioindustry company UPM and shows promising signs for future developments, such as cell therapy. ”We are excited to offer this Finnish product, made from Finnish raw material, first in the world to Finnish healthcare professionals and patients,” said Johana Kuncova-Kallio, Director of UPM Biomedicals. “Nanofibrillar cellulose has proven its potential both in the development of cell therapies and in clinical applications, and we are committed to further innovation.” Kaj Dahlström, CEO of Steripolar, added: “We were attracted to the ingenuity of FibDex. We are always looking for products and solutions that offer diverse and pain-free healing, while minimizing damage to the environment.”
Back To Top
×Close search
Search